Latest News and Press Releases

VANCOUVER, British Columbia and MOUNTAIN VIEW, Calif., Sept. 24, 2020 (GLOBE NEWSWIRE) -- AbCellera and IGM Biosciences, Inc. (Nasdaq: IGMS), announced today that they have entered into a multi-year,...

MOUNTAIN VIEW, Calif., Sept. 02, 2020 (GLOBE NEWSWIRE) -- IGM Biosciences, Inc. (Nasdaq: IGMS), a clinical-stage biotechnology company focused on creating and developing engineered IgM antibodies,...

­  - IND for IGM-8444 for treatment of patients with solid cancers cleared by FDA - - Kathy Miller, Ph.D., appointed Vice President, Antibody Discovery - - Phase I clinical trial of IGM-2323...

MOUNTAIN VIEW, Calif., Aug. 04, 2020 (GLOBE NEWSWIRE) -- IGM Biosciences, Inc. (Nasdaq: IGMS), a clinical-stage biotechnology company focused on creating and developing engineered IgM antibodies,...

MOUNTAIN VIEW, Calif., May 28, 2020 (GLOBE NEWSWIRE) -- IGM Biosciences, Inc. (Nasdaq: IGMS), a clinical-stage biotechnology company focused on creating and developing engineered IgM antibodies,...

MOUNTAIN VIEW, Calif., May 12, 2020 (GLOBE NEWSWIRE) -- IGM Biosciences, Inc. (Nasdaq: IGMS), a clinical-stage biotechnology company focused on creating and developing engineered IgM antibodies,...

- Initial data from Phase 1 trial of IGM-2323 in relapsed/refractory non-Hodgkin’s lymphoma expected in the second half of 2020 - - IND filing for IGM-8444 planned in 2020 - - Collaboration with...

- Companies to utilize proprietary platforms to discover, develop, and manufacture potential therapeutic antibodies to combat ongoing COVID-19 pandemic - SOUTH SAN FRANCISCO, Calif. and CAMBRIDGE,...

MOUNTAIN VIEW, Calif., April 03, 2020 (GLOBE NEWSWIRE) -- IGM Biosciences, Inc. (Nasdaq: IGMS), a clinical-stage biotechnology company focused on creating and developing engineered IgM antibodies,...

- Initial data from Phase 1 trial of IGM-2323 in relapsed/refractory non-Hodgkin’s lymphoma expected in the second half of 2020 - - IND filing for IGM-8444 planned in 2020 - - Company to host...